Posts by Mourabit Halima

Kidney cancer is one of the three most common urological tumors in China, with an increasing incidence rate in recent years. As surgical techniques and new treatment strategies for kidney cancer have advanced, patient survival rates have also improved. At the 2024 Annual Meeting of the Urological Surgeon Branch of the Chinese Medical Doctor Association (CUDA) in Xi'an, Oncology Frontier - Urology NewsUrology Frontier invited Professor He ZhisongDr. Zhisong He from Peking University First Hospital to share insights on the development of kidney cancer surgery in China, second-line treatments for advanced kidney cancer, and progress in the national kidney cancer quality control project.

Non-muscle-invasive bladder cancer (NMIBC) accounts for over 70% of all bladder cancer cases. For NMIBC patients, the primary treatment goals are to eliminate tumor cells, prevent recurrence and progression, while preserving bladder function and quality of life as much as possible. From August 8-11, 2024, the Annual Meeting of the Urological Surgeon Branch of the Chinese Medical Doctor Association (CUDA) was held in Xi'an. Following the event, Urology Frontier invited Dr. Hailong Hu from The Second Hospital of Tianjin Medical University to share insights on the unmet clinical needs of NMIBC patients in China, recent advances in novel treatment strategies, and future development directions.

In the rapidly evolving field of oncology, antibody-drug conjugates (ADCs) have emerged as one of the most promising advancements in targeted cancer therapy. The groundbreaking article titled "Spotlight on Ideal Target Antigens and Resistance in Antibody-Drug Conjugates: Strategies for Competitive Advancement," led by renowned oncologist Academician Binghe Xu, and co-authored by Dr. Mingxia Jiang and Dr. Qiao Li from the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, delves into the intricate world of ADCs. Published in the esteemed Drug Resistance Updates journal with an impact factor of 15.8, this article not only highlights the transformative potential of ADCs in precision oncology but also addresses the formidable challenge of drug resistance that threatens to undermine their efficacy.

In the rapidly evolving field of oncology, breakthroughs are continuously shaping the way we approach the most challenging cancers. One such breakthrough is the potential of Poly (Adenosine Diphosphate-Ribose) Polymerase inhibitors (PARPi) in the treatment of triple-negative breast cancer (TNBC), a particularly aggressive and hard-to-treat subtype of breast cancer. Academician Binghe Xu from the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College has authored a study published in Medicinal Research Reviews, a journal with an impact factor of 10.9. The study, titled “Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous recombination repair deficiency,” explores the potential of novel therapies known as PARP inhibitors. It specifically examines how these therapies can target the unique vulnerabilities of triple-negative breast cancer tumors with homolo

Breast cancer has now become the most common malignant tumor worldwide and is one of the most prevalent cancers among Chinese women, posing a serious threat to their physical and mental health. While significant progress has been made in the treatment and drug development for breast cancer, providing more targeted treatment options for different types of patients and improving survival rates and quality of life, our ultimate goal is to reduce the incidence of breast cancer through screening and prevention. Early detection is crucial for improving treatment outcomes and extending survival times. This article discusses breast cancer screening and how high-risk groups can reduce their risk of developing breast cancer.